

RESPONSE UNDER 37 CFR 1.118
 EXAMINING PROCEDURE
 EXAMINING GROUP 1623

PATENT

Rev 07/05

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED
 CENTRAL FAX CENTER
 OCT 12 2006

In re application : Mitchell P. Fink et al.
 Application No. : 10/659,063
 Filed : September 10, 2003
 Confirmation No. : 3827
 For : EXTRACELLULAR NAD+ AND CADPR AS POTENT
 ANTI-INFLAMMATORY AGENTS
 Examiner : Henry, Michael C.
 Attorney's Docket : UPIIT-008XX

TC Art Unit: 1623

 I hereby certify that this correspondence is being sent via
 facsimile to Examiner Michael C. Henry, TC Art Unit 1623, Fax No.
 (571) 273 8300, on Oct. 12, 2006.

By: Holliday C. Heine
 Holliday C. Heine, Ph.D.
 Registration No. 34,346
 Attorney for Applicant(s)

AMENDMENT PURSUANT TO 37 C.F.R. §1.116

Via Facsimile
 Commissioner for Patents
 P.O. Box 1450
 Alexandria, VA 22313-1450

Sir:

In response to the final Office Action dated June 12, 2006,
 in the above-identified patent application, please amended the
 claims as follows.

WEISMAN, SCHULZ,
 CACERES & LEBOVITZ LLP
 TEL. (617) 542-2290
 FAX. (617) 451-0313

Do
 not
 Enter
 M.C.H.
 11/20/06